MBX Biosciences (MBX): UBS reiterates Buy on MBX ahead of a pivotal Q4 obesity readout

Overview

UBS's NDR takeaways argue that management discussions increased its confidence in MBX Biosciences' obesity portfolio, centered on the Q4 Phase I Part C readout for MBX-4291. UBS reiterates Buy and a US$90 target, viewing the company as undervalued relative to the combined support from its Phase III PTH program and the potential strategic and commercial value of a differentiated long-acting obesity platform.

Core views

UBS frames the Q4 12-week obesity readout for MBX-4291 as the central near-term inflection point. The stock had risen from roughly US$30 to approximately US$60 over the preceding months, which UBS attributes largely to removal of the one-year PTH-data overhang and greater investor focus on obesity. The firm believes the obesity readout could de-risk the program, improve MBX's strategic positioning, and add to a valuation that it says is already fundamentally supported by the Phase III PTH program. UBS reiterates a Buy rating and US$90 target, describing the long-acting obesity portfolio as scarce and underappreciated. For efficacy, UBS wants approximately 6-9% weight loss at week 12, while noting that investors may favor the upper end of the range, or 7-9%. The benchmark is tirzepatide's approximately 8-9% absolute weight loss at week 12 in SURMOUNT-1, versus roughly 2% for placebo. Earlier blinded Part B data showed approximately 7% blended weight loss at week 8 in N=8 patients, including two placebo patients, but UBS stresses that the upcoming Part C study is a distinct N=30 cohort randomized 2:1 to drug and placebo, so the earlier result does not establish the Part C mean. UBS's illustrative pharmacokinetic simulation suggests the Cohort 1 regimen—30 mg weekly for four doses, followed by 120 mg monthly and 180 mg monthly—should produce exposure over weeks 0-12 similar to tirzepatide 5.0 mg weekly. Similar preclinical GLP-1 and GIP receptor-binding activity further supports UBS's expectation that efficacy could be in the same range as tirzepatide's 5.0 mg dose, though it sees no clear basis to expect meaningfully greater efficacy. The proposed differentiation is tolerability and dosing convenience. UBS cites MBX-4291's gradual rise to peak concentration and delayed Tmax of approximately 13-14 days, compared with about two days for tirzepatide and Metsera, as supporting a potentially self-titrating profile. In the initial blinded Part B update, there was one mild diarrhea case and no nausea or vomiting among N=8 patients, although UBS explicitly cautions that this is a very small sample. For Part C, UBS wants GI-event rates at least comparable with, and preferably lower than, tirzepatide's approximately 10% vomiting, 20% diarrhea and 30% nausea benchmarks. The N=30 design means each treatment-arm event represents about a 5% incidence rate, so observed rates may be variable. UBS also highlights a T₁/₂Cmax of about 26 days versus roughly 20-21 days for Metsera as support for long-acting monthly dosing, while recognizing that the transition from weekly dosing in month one to monthly dosing thereafter remains an open development question. Cohort 1 is exploratory, and Cohort 2 could provide further insight into the optimal regimen if reported. UBS sees the obesity opportunity as incremental upside beyond the PTH asset. Its illustrative US opportunity assumes one million treated patients and a US$5,000 annual net price, producing approximately US$5 billion in unadjusted peak sales. The report notes consensus estimates of US$100-150 billion for the 2035 obesity market and argues that a 3-5% share is not overly aggressive for a potentially differentiated product. It also treats Pfizer's acquisition of Metsera, described as approximately US$7 billion in enterprise value with potential additional milestone payments and up to US$9 billion-plus total consideration, as evidence of strategic interest in obesity platforms. UBS's US$90 target is based on a 2x multiple applied to approximately US$2 billion of 2035 probability-adjusted sales across two programs, with DCF support. Its base scenario assumes 50% probability of success for canvuparatide and 15% for obesity, generating US$1.21 billion and US$750 million, respectively, in probability-adjusted sales. The valuation incorporates US$440 million of net cash, a 12% discount rate, options dilution, expected equity changes, and a one-year roll-forward. UBS cites selected public-company multiples with a 1.3x mean and median EV-to-2035-sales multiple, alongside precedent transactions averaging 2.0x, to support its selected 2x multiple.

Analysis framework

UBS combines management-meeting takeaways, Phase I clinical and pharmacokinetic evidence, comparator trial benchmarks, an illustrative PK-exposure simulation, and receptor-binding comparisons to form expectations for the Q4 data. It then values the pipeline through probability-adjusted peak sales, a selected sales multiple, cash and dilution adjustments, a one-year target-price roll-forward, comparable-company and transaction benchmarks, and DCF support.

Methodology notes

• Valuation methodsP/E and PEG Valuation

  Probability-adjusted peak-sales multiple valuation

  UBS applies a 2x multiple to probability-adjusted 2035 sales across two programs, then adjusts for cash, dilution and the forward target-price period.

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow support

  The report says its peak-sales-multiple valuation is further supported by DCF analysis and presents a 12% discount rate in its valuation work.

• Industry AnalysisSupply-demand framework

  Obesity-market penetration and pricing analysis

  UBS estimates potential obesity sales from treated-patient volume, annual net price and assumed market share, linking product differentiation to commercial penetration.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• MBX Biosciences (MBX.US)

  Primary covered company; UBS sees the Phase III PTH program as fundamental valuation support and the obesity portfolio as additional upside.

  Strengths

  Phase III weekly PTH program; potential once-monthly MBX-4291 dosing; gradual PK profile; potential GI-tolerability differentiation; broader obesity pipeline.

  Weaknesses

  The obesity program remains early stage, and the key Part C data are from a small exploratory cohort.

  Comparison

  UBS benchmarks MBX-4291 against tirzepatide on exposure, efficacy and GI tolerability, and views Metsera as the closest strategic comparison.

  Risks

  Weaker-than-expected clinical efficacy, limited differentiation, development delays, safety or tolerability concerns.

• Metsera

  Comparable strategic obesity-platform benchmark following Pfizer's acquisition.

  Strengths

  Its acquisition is cited as evidence of strategic interest in obesity assets.

  Weaknesses

  UBS notes that Metsera may require a more complicated titration schedule to mitigate GI side effects.

  Comparison

  MBX-4291's delayed Tmax and approximately 26-day T₁/₂Cmax are compared with Metsera's faster Tmax and roughly 20-21-day T₁/₂Cmax.

Key data

• 12-month price targetUS$90.00UBS reiterates Buy.
• Share priceUS$55.39Price as of 24 September 2026.
• Forecast price appreciation62.5%UBS forecast return presentation; dividend yield is 0.0%.
• Desired week-12 weight loss~6-9%UBS considers 7-9% the stronger range for the Part C readout.
• Part C study sizeN=30Randomized 2:1 to drug and placebo; 20 patients on drug and 10 on placebo.
• MBX-4291 delayed Tmax~13-14 daysCompared with approximately two days for tirzepatide and Metsera.
• Potential US obesity peak sales~US$5 billionIllustrative estimate based on one million treated patients and a US$5,000 annual net price.
• Valuation basis2x on ~US$2 billion of 2035 probability-adjusted salesAcross two programs, with DCF support.

Impact & implications

UBS argues that competitive week-12 efficacy together with lower or comparable GI-event rates would validate a potentially differentiated once-monthly obesity candidate and could increase MBX's strategic value. The firm views the Q4 data as the main near-term de-risking event, while longer-term upside also depends on development of the broader obesity portfolio, including long-acting amycretin and GGG programs that may enter the clinic in 2027/28.

Risks

• Clinical data may show weaker-than-expected efficacy or insufficient differentiation versus existing obesity therapies.
• Development delays or safety and tolerability concerns could reduce valuation.
• The initial Part B tolerability and weight-loss observations were based on only N=8 patients and may not translate to the separate Part C cohort.
• The optimal transition from weekly dosing in month one to monthly dosing thereafter remains uncertain.

What to watch

• Q4 2026 12-week Phase I Part C Cohort 1 data for MBX-4291.
• Whether week-12 weight loss falls in UBS's approximately 6-9% target range, particularly the 7-9% upper range.
• Part C vomiting, diarrhea and nausea rates relative to UBS's tirzepatide benchmarks of approximately 10%, 20% and 30%, respectively.
• Whether Cohort 2 data are reported and clarify the optimal dosing regimen.
• Progress of the long-acting amycretin and GGG obesity programs, which UBS expects could enter the clinic in 2027/28.